{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OLANZapine+Injection",
    "query": {
      "intervention": "OLANZapine Injection"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OLANZapine+Injection&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T05:27:54.664Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00330863",
      "title": "Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Risperidone microspheres",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 357,
      "start_date": "2006-05",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2018-07-10",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00330863"
    },
    {
      "nct_id": "NCT07570875",
      "title": "Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Ketogenic foodstuffs",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard of Care Oral antipsychotics",
          "type": "OTHER"
        },
        {
          "name": "Standard of care long acting injectable medication for bipolar disorder",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-08",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 1,
      "location_summary": "Montgomery, Alabama",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07570875"
    },
    {
      "nct_id": "NCT03211897",
      "title": "Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Agitation,Psychomotor"
      ],
      "interventions": [
        {
          "name": "Haloperidol Injection",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone Injection",
          "type": "DRUG"
        },
        {
          "name": "OLANZapine Injection",
          "type": "DRUG"
        },
        {
          "name": "Midazolam injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hennepin Healthcare Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 737,
      "start_date": "2017-06-15",
      "completion_date": "2017-10-01",
      "has_results": false,
      "last_update_posted_date": "2018-03-16",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03211897"
    },
    {
      "nct_id": "NCT00320489",
      "title": "Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "olanzapine pamoate depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 524,
      "start_date": "2006-04",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-01-23",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 13,
      "location_summary": "Escondido, California • National City, California • Orange, California + 10 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00320489"
    },
    {
      "nct_id": "NCT02237417",
      "title": "Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Standard of Care Oral antipsychotics",
          "type": "DRUG"
        },
        {
          "name": "IM aripiprazole once monthly",
          "type": "DRUG"
        },
        {
          "name": "No Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 47,
      "start_date": "2014-09-01",
      "completion_date": "2020-07-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237417"
    },
    {
      "nct_id": "NCT01157351",
      "title": "15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "paliperidone",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "haloperidole",
          "type": "DRUG"
        },
        {
          "name": "perphenazine",
          "type": "DRUG"
        },
        {
          "name": "aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "quetiapine",
          "type": "DRUG"
        },
        {
          "name": "paliperidone palmitate",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 450,
      "start_date": "2010-05",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-04-24",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 55,
      "location_summary": "Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more",
      "locations": [
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01157351"
    },
    {
      "nct_id": "NCT00177164",
      "title": "Risperdal Consta for Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar I Disorder"
      ],
      "interventions": [
        {
          "name": "Injectable Risperidone (Consta) or oral antipsychotic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2003-11",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-19",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 4,
      "location_summary": "Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Bridgeville",
          "state": "Pennsylvania"
        },
        {
          "city": "DuBois",
          "state": "Pennsylvania"
        },
        {
          "city": "McKeesport",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00177164"
    },
    {
      "nct_id": "NCT00088465",
      "title": "Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenic Disorders",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Intramuscular olanzapine depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 931,
      "start_date": "2004-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2012-01-11",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 21,
      "location_summary": "Orange, California • Pasadena, California • San Diego, California + 18 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088465"
    },
    {
      "nct_id": "NCT00895921",
      "title": "Examining the Effects of Antipsychotic Medications on Insulin Sensitivity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veterans Medical Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "40 Years to 65 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2008-11",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00895921"
    },
    {
      "nct_id": "NCT00690235",
      "title": "Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Diabetes",
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "Pramlintide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2007-11",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-09-10T05:27:54.664Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690235"
    }
  ]
}